Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Koselugo is a class of finely designed small molecule MEK blockers (also known as mitogen activation inhibitors), and its core therapeutic strategy is targeted therapy for specific···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：322
Koselugo is a precisely targeted small molecule MEK inhibitor with a therapeutic focus on targeted therapies targeting specific tumor types, especially in the treatment of neurofib···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：333
Koselugo is a class of precision small molecule MEK inhibitors (also regarded as schizogenic activation antagonists), and its core efficacy focuses on targeted therapy for specific···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：295
Koselugo is a small molecule MEK inhibitor (figogen activation inhibitor) that is mainly used for the treatment of certain types of tumors, especially in the treatment of neurofibr···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：315
Anamorelin is a drug for cancer cachexia that increases a patient's appetite and weight by mimicking the effects of ghrelin. This drug can significantly improve the nutritional···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：380
As a selective ghrelin receptor agonist, anamolin is approved in Japan for improving the health of cancer cachexia patients. By promoting appetite and gaining weight, it has a posi···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：282
Through its unique pharmacological effects, Anamoreline is effective in helping cancer patients overcome weight loss and loss of appetite. Drugs have shown therapeutic potential in···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：264
Anamorelin helps cancer patients with dyscrasia restore the body's energy supply by stimulating appetite and increasing growth hormone secretion. It is currently the only widel···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：310
In 2021, Japan approved Anamorelin for the treatment of cachexia caused by various cancers such as non-small cell lung cancer. The drug has performed well in multiple clinical tria···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：358
Anamorelin is a novel ghrelin receptor agonist specifically designed for the treatment of cancer cachexia. It provides vital support to patients with advanced cancer by increasing ···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：407
Anamorelin is a selective oral medication that increases a patient's appetite and body weight primarily by activating ghrelin receptors. It is especially suitable for cancer pa···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：324
Anamorelin is a ghrelin receptor agonist that is effective in improving appetite and muscle mass in patients with cancer cachexia. Drugs have shown good results in clinical trials,···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：399
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4442025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6302024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：852026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：4132025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4292025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4152025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4732025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3832025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
